

## Disclaimer

The following report(s) provides findings from an FDA-initiated query using Sentinel. While Sentinel queries may be undertaken to assess potential medical product safety risks, they may also be initiated for various other reasons. Some examples include determining a rate or count of an identified health outcome of interest, examining medical product use, exploring the feasibility of future, more detailed analyses within Sentinel, and seeking to better understand Sentinel capabilities.

FDA wants to emphasize that the fact that FDA has initiated a query involving a medical product and is reporting findings related to that query does not mean that FDA is suggesting health care practitioners should change their prescribing practices for the medical product or that patients taking the medical product should stop using it. Patients who have questions about the use of an identified medical product should contact their health care practitioners.

The following report contains a description of the request, request specifications, and results from the modular program run(s).

If you are using a web page screen reader and are unable to access this document, please contact the Sentinel Operations Center for assistance at [info@sentinelssystem.org](mailto:info@sentinelssystem.org).

**Overview for Request: cder\_iqp\_wp034**

**Request ID:** cder\_iqp\_wp034

**Request Description:** In this report we aimed to characterize users of 51 new molecular entities (NMEs) that were approved by the FDA in 2021 in the TriNetX Live™ platform.

**Data Source:** We ran this query on January 19, 2024. This query contains data from 50 health care organizations (HCOs), provided through the TriNetX Live™ platform in their USA Network with Minimal Shift from December 18, 2020 to the most recently available data, January 19, 2024.

TriNetX aggregates electronic health record (EHR) systems data from its partner HCOs to create queryable datasets. TriNetX datasets primarily comprise clinical patient data such as demographics, diagnoses, procedures, labs, and medications. The USA Network with Minimal Shift contains HCOs that date shift their data by 14 or fewer days (including 0). For more information on the TriNetX Live™ platform and the TriNetX data visit their website here: <https://trinetx.com/>.

**Study Design:** In this retrospective cohort study, we identified counts of individuals with evidence of exposure to the 51 approved NMEs. We built 59 distinct cohorts using the Query Builder module in the TriNetX Live™ platform. We additionally described each cohort's demographic distribution using the Explore Cohort module.

**Exposures of Interest:** We examined 51 NMEs of interest. These included: aducanumab-avwa, amivantamab-vmjw, anifrolumab-fnia, asciminib, asparaginase erwinia chrysanthemi (recombinant)-rywn, atogepant, avacopan, avalglucosidase alfa-ngpt, belumosudil, belzutifan, cabotegravir, cabotegravir and rilpivirine (injectable only), casimersen, dasiglucagon, difelikefalin, dostarlimab-gxly, drospirenone and estetrol, efgartigimod alfa-fcab, evinacumab-dgnb, fexinidazole, finerenone, fosdenopterin, ibrexafungerp, inclisiran, infigratinib, loncastuximab tesirine-lpyl, lonapegsomatropin-tcgd, maralixibat, maribavir, melphalan flufenamide, mobocertinib, odevixibat, olanzapine and samidorphan, pafolacianine, pegcetacoplan, piflufolostat F-18, ponesimod, ropeginterferon alfa-2b-njft, serdexmethylphenidate and dexmethylphenidate, sotorasib, tepotinib, tezepelumab-ekko, tisotumab vedotin-tftv, tivozanib, tralokinumab-ldrm, trilaciclib, umbralisib, vericiguat, viloxazine, voclosporin, and vosoritide.

We used RxNorm medication terms and Healthcare Common Procedure Coding System (HCPCS) procedure codes in the Query Builder module. In order to be included in a cohort, we required evidence of a prescription, administration, or dispensing with the relevant NME of interest (with or without additional filters) between December 18, 2020 and January 19, 2024.

**Sensitivity Analyses:** For certain NME exposures which have non-specific RxNorm medication terms or fixed dose combination/co-packaged NMEs, we used filters for brand names or route of administration in the TriNetX platform to more accurately identify exposures. To this end, we included additional cohorts to compare patient counts with and without the filters. We included the following sensitivity tests:

- \* Asparaginase erwinia chrysanthemi (recombinant)-rywn: with and without brand name Rylaze
- \* Cabotegravir alone: overall, oral only, injectable only, and brand name Apretude or Vocabria. For the overall and oral only cohorts we additionally excluded patients with same-day exposures of rilpivirine.
- \* Efgartigimod alfa-fcab: with and without brand name Vyvgart
- \* Olanzapine and samidorphan: with and without brand name Lybalvi
- \* Pegcetacoplan: with and without brand name Empaveli
- \* Serdexmethylphenidate and dexmethylphenidate: with and without brand name Azstarys

**Please see Appendix A for the list of RxNorm medication terms and HCPCS procedure codes, with information on filters used to define the exposures of interest in this request.**

## Overview for Request: cder\_iqp\_wp034

**Cohort Eligibility Criteria:** We created a separate cohort for each of the 51 NMEs with additional sensitivity cohorts as detailed in the "Exposures of Interest" section (total 59 cohorts). Patients of all ages were included in all the cohorts.

**Please see Appendix B for the specifications of the cohort parameters for each of the 59 cohorts as included in the Query Builder.**

**Limitations:** Algorithms used to define exposures, characteristics, and pregnancy, and mapping of source data to the data model are imperfect and susceptible to misclassification. Additionally, EHR data in the United States lacks longitudinality. The information before or after patients' healthcare encounters could be missing, especially if patient care was administered across different HCOs that may or might not participate in the TriNetX USA network. We are unable to determine if absence of evidence of a condition implies a true absence of a condition or if the condition was not observed in the data. Furthermore, not all HCOs provide brand name or route information for RxNorm terms or laboratory data. Therefore, data should be interpreted with these limitations in mind.

All counts provided through the TriNetX Live™ platform are rounded up to the nearest 10 to protect patient privacy. This rounding affects error, especially as sample sizes decrease. Error due to rounding can range from <0.09% when sample sizes are >10,000 to nearly 20% as sample sizes drop. Thus, all estimates should be interpreted as ranges, and small sample sizes should be interpreted with caution. Additionally, percentages are calculated based on these rounded numerators and denominators. Thus, due to rounding, the sum of each value in a category may not total to 100%.

The TriNetX Live™ platform uses RxNorm terms to identify medications, specifically the primary ingredient RxNorm terms.

- In case of fixed dose combinations/co-packaged medications (four NMEs in this query), the drugs are identified in the platform as the presence of primary ingredient RxNorm terms for all the individual medications on the same day (even if a multiple ingredient RxNorm term is made available by the National Library of Medicine), under the assumption that this refers only to the combined drugs and not two individual drugs prescribed concomitantly. We can have exposure misclassification if the assumption does not hold. To investigate this further, we have created sensitivity analyses cohorts, with and without the brand name/route of administration filter.

- Additionally, the RxNorm terms for certain NMEs in the query were non-specific i.e., referred to more than one drug in the market. E.g., the primary ingredient RxNorm term for Asparaginase erwinia chrysanthemi (recombinant)-rywn (Brand Rylaze, approved in 2021) is the same as for Asparaginase erwinia chrysanthemi (brand Erwinaze, approved in 2011). To investigate such instances further, we have created sensitivity analyses cohorts, with and without the brand name filter.

**Notes:** We ran this query on January 19, 2024. A re-run of this query for the same query period in the future may not yield the same results owing to the dynamic nature of the TriNetX Live™ network.

Please contact the Sentinel Operations Center ([info@sentinelssystem.org](mailto:info@sentinelssystem.org)) for questions and to provide comments/suggestions for future enhancements to this document. For more information on Sentinel's querying in the TriNetX platform, please refer to the Sentinel Website (<https://www.sentinelinitiative.org/methods-data-tools/methods/trinetx-rapid-querying>).

**Table of Contents**

<b>Glossary</b>	Glossary of Terms for Analyses Using TriNetX Live™ Platform
<b>Figure 1</b>	Demographic Characteristics for Patients with Aducanumab-avwa Exposures, from December 18, 2020 through January 19, 2024
<b>Figure 2</b>	Demographic Characteristics for Patients with Amivantamab-vmjw Exposures, from December 18, 2020 through January 19, 2024
<b>Figure 3</b>	Demographic Characteristics for Patients with Anifrolumab-fnia Exposures, from December 18, 2020 through January 19, 2024
<b>Figure 4</b>	Demographic Characteristics for Patients with Asciminib Exposures, from December 18, 2020 through January 19, 2024
<b>Figure 5</b>	Demographic Characteristics for All Patients with Asparaginase Erwinia Chrysanthemi (Recombinant)-rywn Exposures, from December 18, 2020 through January 19, 2024
<b>Figure 6</b>	Demographic Characteristics for Patients with Asparaginase Erwinia Chrysanthemi (Recombinant)-rywn Exposures, Restricted to Brand Name Rylaze, from December 18, 2020 through January 19, 2024
<b>Figure 7</b>	Demographic Characteristics for Patients with Atogepant Exposures, from December 18, 2020 through January 19, 2024
<b>Figure 8</b>	Demographic Characteristics for Patients with Avacopan Exposures, from December 18, 2020 through January 19, 2024
<b>Figure 9</b>	Demographic Characteristics for Patients with Avalglucosidase alfa-ngpt Exposures, from December 18, 2020 through January 19, 2024
<b>Figure 10</b>	Demographic Characteristics for Patients with Belumosudil Exposures, from December 18, 2020 through January 19, 2024
<b>Figure 11</b>	Demographic Characteristics for Patients with Belzutifan Exposures, from December 18, 2020 through January 19, 2024
<b>Figure 12</b>	Demographic Characteristics for All Patients with Cabotegravir Exposures, from December 18, 2020 through January 19, 2024
<b>Figure 13</b>	Demographic Characteristics for Patients with Cabotegravir Exposures, Restricted to Oral Exposures, from December 18, 2020 through January 19, 2024
<b>Figure 14</b>	Demographic Characteristics for Patients with Cabotegravir Exposures, Restricted to Injectable Exposures, from December 18, 2020 through January 19, 2024
<b>Figure 15</b>	Demographic Characteristics for Patients with Cabotegravir Exposures, Restricted to Brand Names Apretude or Vocabria, from December 18, 2020 through January 19, 2024
<b>Figure 16</b>	Demographic Characteristics for All Patients with Injectable Cabotegravir and Rilpivirine Exposures, from December 18, 2020 through January 19, 2024

**Table of Contents**

<b>Figure 17</b>	Demographic Characteristics for Patients with Casimersen Exposures, from December 18, 2020 through January 19, 2024
<b>Figure 18</b>	Demographic Characteristics for Patients with Dasiglucagon Exposures, from December 18, 2020 through January 19, 2024
<b>Figure 19</b>	Demographic Characteristics for Patients with Difelikefalin Exposures, from December 18, 2020 through January 19, 2024
<b>Figure 20</b>	Demographic Characteristics for Patients with Dostarlimab-gxly Exposures, from December 18, 2020 through January 19, 2024
<b>Figure 21</b>	Demographic Characteristics for All Patients with Drospirenone and Estetrol Exposures, from December 18, 2020 through January 19, 2024
<b>Figure 22</b>	Demographic Characteristics for All Patients with Efgartigimod alfa-fcab Exposures, from December 18, 2020 through January 19, 2024
<b>Figure 23</b>	Demographic Characteristics for Patients with Efgartigimod alfa-fcab Exposures, Restricted to Brand Name Vyvgart, from December 18, 2020 through January 19, 2024
<b>Figure 24</b>	Demographic Characteristics for Patients with Evinacumab-dgnb Exposures, from December 18, 2020 through January 19, 2024
<b>Figure 25</b>	Demographic Characteristics for Patients with Fexinidazole Exposures, from December 18, 2020 through January 19, 2024
<b>Figure 26</b>	Demographic Characteristics for Patients with Finerenone Exposures, from December 18, 2020 through January 19, 2024
<b>Figure 27</b>	Demographic Characteristics for Patients with Fosdenopterin Exposures, from December 18, 2020 through January 19, 2024
<b>Figure 28</b>	Demographic Characteristics for Patients with Ibrexafungerp Exposures, from December 18, 2020 through January 19, 2024
<b>Figure 29</b>	Demographic Characteristics for Patients with Inclisiran Exposures, from December 18, 2020 through January 19, 2024
<b>Figure 30</b>	Demographic Characteristics for Patients with Infigratinib Exposures, from December 18, 2020 through January 19, 2024
<b>Figure 31</b>	Demographic Characteristics for Patients with Loncastuximab Tesirine-lpyl Exposures, from December 18, 2020 through January 19, 2024
<b>Figure 32</b>	Demographic Characteristics for Patients with Lonapegsomatropin-tcgd Exposures, from December 18, 2020 through January 19, 2024

**Table of Contents**

<b>Figure 33</b>	Demographic Characteristics for Patients with Maralixibat Exposures, from December 18, 2020 through January 19, 2024
<b>Figure 34</b>	Demographic Characteristics for Patients with Maribavir Exposures, from December 18, 2020 through January 19, 2024
<b>Figure 35</b>	Demographic Characteristics for Patients with Melphalan Flufenamide Exposures, from December 18, 2020 through January 19, 2024
<b>Figure 36</b>	Demographic Characteristics for Patients with Mobocertinib Exposures, from December 18, 2020 through January 19, 2024
<b>Figure 37</b>	Demographic Characteristics for Patients with Odevixibat Exposures, from December 18, 2020 through January 19, 2024
<b>Figure 38</b>	Demographic Characteristics for All Patients with Olanzapine and Samidorphan Exposures, from December 18, 2020 through January 19, 2024
<b>Figure 39</b>	Demographic Characteristics for Patients with Olanzapine and Samidorphan Exposures, Restricted to Brand Name Lybalvi, from December 18, 2020 through January 19, 2024
<b>Figure 40</b>	Demographic Characteristics for Patients with Pafolacianine Exposures, from December 18, 2020 through January 19, 2024
<b>Figure 41</b>	Demographic Characteristics for All Patients with Pegcetacoplan Exposures, from December 18, 2020 through January 19, 2024
<b>Figure 42</b>	Demographic Characteristics for Patients with Pegcetacoplan Exposures, Restricted to Brand Name Empaveli, from December 18, 2020 through January 19, 2024
<b>Figure 43</b>	Demographic Characteristics for Patients with Piflufolastat F-18 Exposures, from December 18, 2020 through January 19, 2024
<b>Figure 44</b>	Demographic Characteristics for Patients with Ponesimod Exposures, from December 18, 2020 through January 19, 2024
<b>Figure 45</b>	Demographic Characteristics for Patients with Roppeginterferon alfa-2b-njft Exposures, from December 18, 2020 through January 19, 2024
<b>Figure 46</b>	Demographic Characteristics for All Patients with Serdexmethylphenidate and Dexmethylphenidate Exposures, from December 18, 2020 through January 19, 2024
<b>Figure 47</b>	Demographic Characteristics for Patients with Serdexmethylphenidate and Dexmethylphenidate Exposures, Restricted to Brand Name Azstarys, from December 18, 2020 through January 19, 2024
<b>Figure 48</b>	Demographic Characteristics for Patients with Sotorasib Exposures, from December 18, 2020 through January 19, 2024

**Table of Contents**

<b>Figure 49</b>	Demographic Characteristics for Patients with Tepotinib Exposures, from December 18, 2020 through January 19, 2024
<b>Figure 50</b>	Demographic Characteristics for Patients with Tezepelumab-ekko Exposures, from December 18, 2020 through January 19, 2024
<b>Figure 51</b>	Demographic Characteristics for Patients with Tisotumab Vedotin-tftv Exposures, from December 18, 2020 through January 19, 2024
<b>Figure 52</b>	Demographic Characteristics for Patients with Tivozanib Exposures, from December 18, 2020 through January 19, 2024
<b>Figure 53</b>	Demographic Characteristics for Patients with Tralokinumab-ldrm Exposures, from December 18, 2020 through January 19, 2024
<b>Figure 54</b>	Demographic Characteristics for Patients with Trilaciclib Exposures, from December 18, 2020 through January 19, 2024
<b>Figure 55</b>	Demographic Characteristics for Patients with Umbralisib Exposures, from December 18, 2020 through January 19, 2024
<b>Figure 56</b>	Demographic Characteristics for Patients with Vericiguat Exposures, from December 18, 2020 through January 19, 2024
<b>Figure 57</b>	Demographic Characteristics for Patients with Viloxazine Exposures, from December 18, 2020 through January 19, 2024
<b>Figure 58</b>	Demographic Characteristics for Patients with Voclosporin Exposures, from December 18, 2020 through January 19, 2024
<b>Figure 59</b>	Demographic Characteristics for Patients with Vosoritide Exposures, from December 18, 2020 through January 19, 2024
<b>Appendix A</b>	List of RxNorm Medication Terms and Healthcare Common Procedure Coding System (HCPCS) Procedure Codes Used to Define Exposures in this Request
<b>Appendix B</b>	Specifications Defining Query Builder Modules in this Request

### Glossary of Terms for Analyses Using TriNetX Live™ Platform\*

- Characteristic** - A medical fact (e.g., diagnosis, procedure, lab result) that occurred on or before the cohort-defining index event.
- Explore Cohort** - A description module on the TriNetX platform that presents a clinical profile of patients in a given cohort. Patient counts are rounded up to the nearest 10 before percentages are calculated, so the sum each of the values in one category may not total to 100%.
- Date Shifting** - A data obfuscation technique that some HCOs use to preserve patient privacy. Date shifting entails assigning each patient a random number of days (eg, -365 to +365 days) and consistently adjusting each of their dates by that number of days, thus maintaining temporal relationships between records within a single patient.
- Fact** - (Medical Fact) A unit of utilization that represents a medical observation on a patient (e.g., diagnosis, procedure, clinical observation).
- Filter** - A method of limiting terms included in queries to a specific subset of data. Filters include age at time of event, data source (electronic health record or natural language processing); brand name, route, and strength for medication terms; occurrence (first or most recent) for lab terms; and priority for diagnosis and procedure terms.
- Group** - A series of codes and terms defined with Boolean logic that are used to create a query cohort. For each group, users have the ability to specified time periods of interest, and the number of instances that the group must occur for cohort entry.
- Subgroup** - Within a group, additional subgroups can be specified to define temporal relationships between the terms in the subgroup (e.g., terms in subgroup B must occur within 5 days after terms in subgroup A). Users can require that these temporal constraints be applied to the 1) first, 2) last, or 3) any instance of each subgroup.
- Health Care Organization (HCO)** - Organizations that contribute electronic healthcare record data to the TriNetX data networks. HCOs include academic institutions and community health provider systems and a single HCO may contain one or more individual sites or facilities.
- Index** - The first date when a patient meets all of the cohort-defining criteria. In Analytics modules, the index can be defined as the date when a patient meets all of the cohort criteria, or only one specific group's criteria.
- Module** - A subsection of the TriNetX platform that performs a distinct functionality. Cohorts are created using the Query Builder module. Descriptive modules include Healthcare Organizations, Explore Cohorts, Rate of Arrival, Summary Statistics, and Analyze Criteria. Advanced analytic modules include Analyze Outcomes, Compare Outcomes, Compare Cohorts, Treatment Pathways, and Incidence and Prevalence.
- Network** - An aggregation of HCOs contributing data to the platform. Multiple networks are available for querying on the platform; the different networks represent subsets of HCOs organized by date-shifting practices or availability of downloadable datasets.
- Outcome** - A medical fact (e.g., diagnosis, procedure, lab result) that occurred on or after the cohort-defining index event.
- Query** - In the TriNetX platform, a query is a distinct cohort with a unique set of terms and logic. Query cohorts are created using the Query Builder platform module.
- Risk** - In Advanced Analytics modules, risk refers to the percentage of patients in each cohort with the specified outcome of interest.
- Priority** - An indication whether the code was the condition that the provider spent the most time evaluating or treating during a visit. Possible values include primary, secondary, or unknown.
- Term** - The codes used to specify patient cohort criteria in a query. Code options include diagnoses, procedures, medications, labs, demographics, genomics, and visits. Terms can be linked together using and/or Boolean logic. TriNetX also creates terms that group together multiple medical codes into single clinical concepts.
- Cannot Have Term** - A category of terms within a query group that patients must not have evidence of to be included in the cohort.
- Must Have Term** - A category of terms within a query group that patients must have evidence of to be included in the cohort.

**Time Constraint** - used to define time periods of interest for each group within a query. Time constraints can be defined relative to the date the query was run (e.g., any time before today), or defined based on specific dates (e.g., January 1, 2015 to September 30, 2020).


**Treatment Pathway** - In Advanced Analytics modules, the Treatment Pathways module returns the order in which patients received treatment and the prevalence of treatments, including combination of medications, following an index event.

**TriNetX Codes** - For commonly used laboratory terms, TriNetX aggregates Logical Observation Identifiers Names and Codes (LOINC) laboratory codes at a clinically significant level to new queryable TNX:LAB terms.

**Visit** - A type of term used to specify the type of medical encounter or facility where the encounter was recorded. Visit terms are derived by TriNetX from the source data. Visits are recorded separately from the codes or labs that occurred during the encounter; care settings are not attached to individual codes. Values for visit terms include: ambulatory, emergency, field, home health, inpatient encounter, inpatient acute, inpatient non-acute, laboratory, observation, pharmacy, pre-admission, short stay, virtual, and unknown.


\*all terms may not be used in this report

**Figure 1. Demographic Characteristics for Patients with Aducanumab-avwa Exposures, from December 18, 2020 through January 19, 2024**




Total Patients	Minimum Age	Maximum Age	Mean Age	Standard Deviation
<b>160</b>	<b>43</b>	<b>90</b>	<b>75</b>	<b>8</b>


**Sex**




**Ethnicity**



**Race**




**Figure 2. Demographic Characteristics for Patients with Amivantamab-vmjw Exposures, from December 18, 2020 through January 19, 2024**



Total Patients	Minimum Age	Maximum Age	Mean Age	Standard Deviation
130	5	90	63	15


**Sex**




**Ethnicity**



**Race**




**Figure 3. Demographic Characteristics for Patients with Anifrolumab-fnia Exposures, from December 18, 2020 through January 19, 2024**




Total Patients	Minimum Age	Maximum Age	Mean Age	Standard Deviation
620	1	81	46	13


**Sex**




**Ethnicity**



**Race**




**Figure 4. Demographic Characteristics for Patients with Asciminib Exposures, from December 18, 2020 through January 19, 2024**




Patients 90 and Older: 4

Total Patients	Minimum Age	Maximum Age	Mean Age	Standard Deviation
<b>480</b>	<b>23</b>	<b>90</b>	<b>58</b>	<b>15</b>


**Sex**




**Ethnicity**






**Race**



**Figure 5. Demographic Characteristics for All Patients\* with Asparaginase Erwinia Chrysanthemi (Recombinant)-rywn Exposures, from December 18, 2020 through January 19, 2024**




Total Patients	Minimum Age	Maximum Age	Mean Age	Standard Deviation
<b>670</b>	<b>0</b>	<b>90</b>	<b>15</b>	<b>13</b>




\*No filters used

**Figure 6. Demographic Characteristics for Patients with Asparaginase Erwinia Chrysanthemi (Recombinant)-rywn Exposures, Restricted to Brand Name Rylaze, from December 18, 2020 through January 19, 2024**




Total Patients	Minimum Age	Maximum Age	Mean Age	Standard Deviation
<b>250</b>	<b>0</b>	<b>50</b>	<b>12</b>	<b>8</b>


**Sex**




**Ethnicity**



**Race**




**Figure 7. Demographic Characteristics for Patients with Atogepant Exposures, from December 18, 2020 through January 19, 2024**




Patients 90 and Older: 13

Total Patients	Minimum Age	Maximum Age	Mean Age	Standard Deviation
17,590	12	90	46	15


### Sex




### Ethnicity



### Race




**Figure 8. Demographic Characteristics for Patients with Avacopan Exposures, from December 18, 2020 through January 19, 2024**




Patients 90 and Older: 1

Total Patients	Minimum Age	Maximum Age	Mean Age	Standard Deviation
260	17	90	57	19


**Sex**




**Ethnicity**



**Race**




**Figure 9. Demographic Characteristics for Patients with Avalglucosidase alfa-ngpt Exposures, from December 18, 2020 through January 19, 2024**




Patients 90 and Older: 0

Total Patients	Minimum Age	Maximum Age	Mean Age	Standard Deviation
90	2	82	40	24


**Sex**




**Ethnicity**



**Race**




**Figure 10. Demographic Characteristics for Patients with Belumosudil Exposures, from December 18, 2020 through January 19, 2024**




Total Patients	Minimum Age	Maximum Age	Mean Age	Standard Deviation
<b>650</b>	<b>3</b>	<b>82</b>	<b>53</b>	<b>18</b>


**Sex**




**Race**



**Ethnicity**




**Figure 11. Demographic Characteristics for Patients with Belzutifan Exposures, from December 18, 2020 through January 19, 2024**




Total Patients	Minimum Age	Maximum Age	Mean Age	Standard Deviation
320	12	89	54	18


**Sex**




**Ethnicity**



**Race**




**Figure 12. Demographic Characteristics for All\* Patients with Cabotegravir Exposures, from December 18, 2020 through January 19, 2024**




Total Patients	Minimum Age	Maximum Age	Mean Age	Standard Deviation
1,270	16	90	36	11


**Sex**



**Race**




**Ethnicity**




\*All Patients with Cabotegravir Exposures Cannot Have Same Day Rilpivirine Exposure  
*The exception added to avoid inclusion of cabotegravir-rilpivirine co-packaged medication*

**Figure 13. Demographic Characteristics for Patients with Cabotegravir Exposures, Restricted to Oral Exposures, from December 18, 2020 through January 19, 2024**




Total Patients	Minimum Age	Maximum Age	Mean Age	Standard Deviation
<b>1,300</b>	<b>18</b>	<b>84</b>	<b>43</b>	<b>13</b>


**Sex**




**Race**



**Ethnicity**




**Figure 14. Demographic Characteristics for Patients with Cabotegravir Exposures\*, Restricted to Injectable Exposures, from December 18, 2020 through January 19, 2024**




Patients 90 and Older: 1

Total Patients	Minimum Age	Maximum Age	Mean Age	Standard Deviation
1,080	16	90	36	11


**Sex**



**Race**




**Ethnicity**



\*All Patients with Injectable Cabotegravir Exposures Cannot Have Same Day Rilpivirine Exposure  
*The exception added to avoid inclusion of cabotegravir-rilpivirine co-packaged medication*


**Figure 15. Demographic Characteristics for Patients with Cabotegravir Exposures, Restricted to Brand Names Apretude or Vocabria, from December 18, 2020 through January 19, 2024**




Patients 90 and Older: 1

Total Patients	Minimum Age	Maximum Age	Mean Age	Standard Deviation
<b>940</b>	<b>18</b>	<b>90</b>	<b>41</b>	<b>13</b>


**Sex**




**Ethnicity**



**Race**




**Figure 16. Demographic Characteristics for All Patients with Injectable Cabotegravir and Rilpivirine Exposures\*, from December 18, 2020 through January 19, 2024**




Total Patients	Minimum Age	Maximum Age	Mean Age	Standard Deviation
<b>3,410</b>	<b>1</b>	<b>88</b>	<b>44</b>	<b>13</b>


**Sex**



**Ethnicity**



**Race**




\*The injectable cabotegravir and rilpivirine exposures occur on the same day.




Assumption is that the same day exposure refers to co-packaged cabotegravir and rilpivirine (brand name Cabenuva).

There is no sensitivity analyses cohort for this combination with a filter for brand name as Cabenuva is not available as a filter option on TriNetX.


**Figure 17. Demographic Characteristics for Patients with Casimersen Exposures, from December 18, 2020 through January 19, 2024**



Total Patients	Minimum Age	Maximum Age	Mean Age	Standard Deviation
60	3	41	16	8




**Figure 18. Demographic Characteristics for Patients with Dasiglucagon Exposures, from December 18, 2020 through January 19, 2024**




Patients 90 and Older: 0

Total Patients	Minimum Age	Maximum Age	Mean Age	Standard Deviation
<b>810</b>	<b>0</b>	<b>85</b>	<b>40</b>	<b>21</b>


**Sex**




**Ethnicity**



**Race**




**Figure 19. Demographic Characteristics for Patients with Difelikefalin Exposures, from December 18, 2020 through January 19, 2024**



Total Patients	Minimum Age	Maximum Age	Mean Age	Standard Deviation
20	32	90	64	17


**Sex**




**Ethnicity**



**Race**




**Figure 20. Demographic Characteristics for Patients with Dostarlimab-gxly Exposures, from December 18, 2020 through January 19, 2024**




Total Patients	Minimum Age	Maximum Age	Mean Age	Standard Deviation
200	26	90	63	13


### Sex




### Race



### Ethnicity




**Figure 21. Demographic Characteristics for All Patients with Drospirenone and Estetrol Exposures\*, from December 18, 2020 through January 19, 2024**




Total Patients	Minimum Age	Maximum Age	Mean Age	Standard Deviation
1,570	13	74	29	10


**Sex**



**Ethnicity**




**Race**




\*The drospirenone and estetrol exposures occur on the same day.  
 Assumption is that the same day exposure refers to fixed dose combination of drospirenone and estetrol.  
 There is no sensitivity analyses cohort for this combination with a filter for brand name.  
 The brand name NextStellis is not available as a filter option on TriNetX.

**Figure 22. Demographic Characteristics for All Patients\* with Efgartigimod alfa-fcab Exposures, from December 18, 2020 through January 19, 2024**




Total Patients	Minimum Age	Maximum Age	Mean Age	Standard Deviation
<b>360</b>	<b>7</b>	<b>90</b>	<b>63</b>	<b>17</b>


**Sex**



**Ethnicity**




**Race**



\*No filters used


**Figure 23. Demographic Characteristics for Patients with Efgartigimod alfa-fcab Exposures, Restricted to Brand Name Vyvgart, from December 18, 2020 through January 19, 2024**




Patients 90 and Older: 0

Total Patients	Minimum Age	Maximum Age	Mean Age	Standard Deviation
140	19	89	62	17


**Sex**




**Race**



**Ethnicity**




**Figure 24. Demographic Characteristics for Patients with Evinacumab-dgnb Exposures, from December 18, 2020 through January 19, 2024**



Patients 90 and Older: 0

Total Patients	Minimum Age	Maximum Age	Mean Age	Standard Deviation
<b>30</b>	<b>5</b>	<b>69</b>	<b>42</b>	<b>22</b>


**Sex**



**Ethnicity**



**Race**




**Figure 25. Demographic Characteristics for Patients with Fexinidazole Exposures, from December 18, 2020 through January 19, 2024**

---


**No patients were identified for this cohort.**

**Figure 26. Demographic Characteristics for Patients with Finerenone Exposures, from December 18, 2020 through January 19, 2024**




Total Patients	Minimum Age	Maximum Age	Mean Age	Standard Deviation
<b>3,810</b>	<b>15</b>	<b>90</b>	<b>68</b>	<b>12</b>


**Sex**




**Race**



**Ethnicity**




**Figure 27. Demographic Characteristics for Patients with Fosdenopterin Exposures, from December 18, 2020 through January 19, 2024**



Total Patients	Minimum Age	Maximum Age	Mean Age	Standard Deviation
20	2	81	51	27


**Sex**




**Ethnicity**



**Race**



**Figure 28. Demographic Characteristics for Patients with Ibrexafungerp Exposures, from December 18, 2020 through January 19, 2024**




Patients 90 and Older: 3

Total Patients	Minimum Age	Maximum Age	Mean Age	Standard Deviation
<b>1,360</b>	<b>12</b>	<b>90</b>	<b>42</b>	<b>15</b>


### Sex




### Ethnicity



### Race




**Figure 29. Demographic Characteristics for Patients with Inclisiran Exposures, from December 18, 2020 through January 19, 2024**




Patients 90 and Older: 13

Total Patients	Minimum Age	Maximum Age	Mean Age	Standard Deviation
2,230	20	90	69	10


**Sex**




**Race**



**Ethnicity**



**Figure 30. Demographic Characteristics for Patients with Infigratinib Exposures, from December 18, 2020 through January 19, 2024**



Total Patients	Minimum Age	Maximum Age	Mean Age	Standard Deviation
<b>30</b>	<b>7</b>	<b>88</b>	<b>62</b>	<b>19</b>


**Sex**




**Ethnicity**






**Race**




**Figure 31. Demographic Characteristics for Patients with Loncastuximab Tesirine-Ipyl Exposures, from December 18, 2020 through January 19, 2024**



Total Patients	Minimum Age	Maximum Age	Mean Age	Standard Deviation
120	24	90	67	15




**Figure 32. Demographic Characteristics for Patients with Lonapegsomatropin-tcgd Exposures, from December 18, 2020 through January 19, 2024**




Total Patients	Minimum Age	Maximum Age	Mean Age	Standard Deviation
770	3	54	12	4


### Sex




### Ethnicity



### Race




**Figure 33. Demographic Characteristics for Patients with Maralixibat Exposures, from December 18, 2020 through January 19, 2024**




Total Patients	Minimum Age	Maximum Age	Mean Age	Standard Deviation
80	0	53	10	11


**Sex**




**Ethnicity**



**Race**




**Figure 34. Demographic Characteristics for Patients with Maribavir Exposures, from December 18, 2020 through January 19, 2024**




Total Patients	Minimum Age	Maximum Age	Mean Age	Standard Deviation
<b>460</b>	<b>2</b>	<b>84</b>	<b>53</b>	<b>19</b>


**Sex**




**Ethnicity**



**Race**




**Figure 35. Demographic Characteristics for Patients with Melphalan Flufenamide Exposures, from December 18, 2020 through January 19, 2024**




Total Patients	Minimum Age	Maximum Age	Mean Age	Standard Deviation
<b>70</b>	<b>2</b>	<b>90</b>	<b>55</b>	<b>20</b>


**Sex**




**Race**



**Ethnicity**




**Figure 36. Demographic Characteristics for Patients with Mobocertinib Exposures, from December 18, 2020 through January 19, 2024**




Patients 90 and Older: 4

Total Patients	Minimum Age	Maximum Age	Mean Age	Standard Deviation
<b>80</b>	<b>28</b>	<b>90</b>	<b>67</b>	<b>14</b>


**Sex**




**Ethnicity**



**Race**




**Figure 37. Demographic Characteristics for Patients with Odevixibat Exposures, from December 18, 2020 through January 19, 2024**




Patients 90 and Older: 0

Total Patients	Minimum Age	Maximum Age	Mean Age	Standard Deviation
60	0	53	12	11


**Sex**




**Ethnicity**



**Race**




**Figure 38. Demographic Characteristics for All Patients with Olanzapine and Samidorphan Exposures\*, from December 18, 2020 through January 19, 2024**




Total Patients	Minimum Age	Maximum Age	Mean Age	Standard Deviation
720	12	90	44	16


**Sex**



**Race**




**Ethnicity**



\*The olanzapine and samidorphan exposures occur on the same day.

Assumption is that the same day exposure refers to fixed dose combination of olanzapine and samidorphan


**Figure 39. Demographic Characteristics for Patients with Olanzapine and Samidorphan Exposures, Restricted to Brand Name Lybalvi, from December 18, 2020 through January 19, 2024**




Patients 90 and Older: 1

Total Patients	Minimum Age	Maximum Age	Mean Age	Standard Deviation
<b>430</b>	<b>14</b>	<b>90</b>	<b>44</b>	<b>16</b>


**Sex**



**Ethnicity**



**Race**




**Figure 40. Demographic Characteristics for Patients with Pafolacianine Exposures, from December 18, 2020 through January 19, 2024**

---


**No patients were identified for this cohort.**

**Figure 41. Demographic Characteristics for All Patients\* with Pegcetacoplan Exposures, from December 18, 2020 through January 19, 2024**




Total Patients	Minimum Age	Maximum Age	Mean Age	Standard Deviation
<b>170</b>	<b>11</b>	<b>90</b>	<b>74</b>	<b>16</b>


**Sex**



**Ethnicity**




**Race**




\*No filters used

**Figure 42. Demographic Characteristics for Patients with Pegcetacoplan Exposures, Restricted to Brand Name Empaveli, from December 18, 2020 through January 19, 2024**




Total Patients	Minimum Age	Maximum Age	Mean Age	Standard Deviation
<b>20</b>	<b>22</b>	<b>74</b>	<b>45</b>	<b>16</b>


**Sex**




**Race**



**Ethnicity**




**Figure 43. Demographic Characteristics for Patients with Piflufolostat F-18 Exposures, from December 18, 2020 through January 19, 2024**




Total Patients	Minimum Age	Maximum Age	Mean Age	Standard Deviation
11,790	5	90	72	8


### Sex




### Ethnicity



### Race




**Figure 44. Demographic Characteristics for Patients with Ponesimod Exposures, from December 18, 2020 through January 19, 2024**




Total Patients	Minimum Age	Maximum Age	Mean Age	Standard Deviation
<b>110</b>	<b>22</b>	<b>83</b>	<b>47</b>	<b>12</b>


**Sex**




**Race**



**Ethnicity**




**Figure 45. Demographic Characteristics for Patients with Ropeginterferon alfa-2b-njft Exposures, from December 18, 2020 through January 19, 2024**




Total Patients	Minimum Age	Maximum Age	Mean Age	Standard Deviation
<b>390</b>	<b>14</b>	<b>87</b>	<b>57</b>	<b>15</b>


**Sex**




**Ethnicity**



**Race**




**Figure 46. Demographic Characteristics for All Patients with Serdexmethylphenidate and Dexmethylphenidate Exposures\*, from December 18, 2020 through January 19, 2024**




Total Patients	Minimum Age	Maximum Age	Mean Age	Standard Deviation
2,670	4	83	20	14


**Sex**



**Race**




**Ethnicity**



\*The serdexmethylphenidate and dexmethylphenidate exposures occur on the same day.


Assumption is that the same day exposure refers to fixed dose combination of serdexmethylphenidate and dexmethylphenidate

**Figure 47. Demographic Characteristics for Patients with Serdexmethylphenidate and Dexmethylphenidate Exposures, Restricted to Brand Name Azstarys, from December 18, 2020 through January 19, 2024**




Total Patients	Minimum Age	Maximum Age	Mean Age	Standard Deviation
<b>1,610</b>	<b>4</b>	<b>77</b>	<b>20</b>	<b>14</b>


**Sex**




**Ethnicity**



**Race**




**Figure 48. Demographic Characteristics for Patients with Sotorasib Exposures, from December 18, 2020 through January 19, 2024**




Patients 90 and Older: 19

Total Patients	Minimum Age	Maximum Age	Mean Age	Standard Deviation
<b>810</b>	<b>25</b>	<b>90</b>	<b>69</b>	<b>11</b>


**Sex**




**Race**



**Ethnicity**




**Figure 49. Demographic Characteristics for Patients with Tepotinib Exposures, from December 18, 2020 through January 19, 2024**




Total Patients	Minimum Age	Maximum Age	Mean Age	Standard Deviation
90	39	90	74	12


### Sex




### Race



### Ethnicity




**Figure 50. Demographic Characteristics for Patients with Tezepelumab-ekko Exposures, from December 18, 2020 through January 19, 2024**




Patients 90 and Older: 4

Total Patients	Minimum Age	Maximum Age	Mean Age	Standard Deviation
1,590	0	90	55	17


**Sex**




**Ethnicity**



**Race**




**Figure 51. Demographic Characteristics for Patients with Tisotumab Vedotin-tftv Exposures, from December 18, 2020 through January 19, 2024**




Total Patients	Minimum Age	Maximum Age	Mean Age	Standard Deviation
130	28	83	53	13


**Sex**




**Race**



**Ethnicity**




**Figure 52. Demographic Characteristics for Patients with Tivozanib Exposures, from December 18, 2020 through January 19, 2024**




Patients 90 and Older: 2

Total Patients	Minimum Age	Maximum Age	Mean Age	Standard Deviation
270	39	90	66	10


**Sex**




**Ethnicity**



**Race**




**Figure 53. Demographic Characteristics for Patients with Tralokinumab-ldrm Exposures, from December 18, 2020 through January 19, 2024**




Total Patients	Minimum Age	Maximum Age	Mean Age	Standard Deviation
580	3	90	51	19


**Sex**




**Ethnicity**



**Race**




**Figure 54. Demographic Characteristics for Patients with Trilaciclib Exposures, from December 18, 2020 through January 19, 2024**




Total Patients	Minimum Age	Maximum Age	Mean Age	Standard Deviation
<b>60</b>	<b>43</b>	<b>90</b>	<b>69</b>	<b>10</b>


**Sex**




**Race**



**Ethnicity**




**Figure 55. Demographic Characteristics for Patients with Umbrisib Exposures, from December 18, 2020 through January 19, 2024**




Patients 90 and Older: 3

Total Patients	Minimum Age	Maximum Age	Mean Age	Standard Deviation
<b>90</b>	<b>41</b>	<b>90</b>	<b>70</b>	<b>11</b>


**Sex**




**Ethnicity**



**Race**




**Figure 56. Demographic Characteristics for Patients with Vericiguat Exposures, from December 18, 2020 through January 19, 2024**




Patients 90 and Older: 46

Total Patients	Minimum Age	Maximum Age	Mean Age	Standard Deviation
<b>1,360</b>	<b>22</b>	<b>90</b>	<b>68</b>	<b>13</b>


**Sex**




**Race**



**Ethnicity**




**Figure 57. Demographic Characteristics for Patients with Viloxazine Exposures, from December 18, 2020 through January 19, 2024**




Total Patients	Minimum Age	Maximum Age	Mean Age	Standard Deviation
<b>6,510</b>	<b>4</b>	<b>81</b>	<b>18</b>	<b>13</b>


**Sex**




**Race**



**Ethnicity**




**Figure 58. Demographic Characteristics for Patients with Voclosporin Exposures, from December 18, 2020 through January 19, 2024**




Total Patients	Minimum Age	Maximum Age	Mean Age	Standard Deviation
<b>320</b>	<b>15</b>	<b>78</b>	<b>39</b>	<b>13</b>


**Sex**




**Ethnicity**



**Race**




**Figure 59. Demographic Characteristics for Patients with Vosoritide Exposures, from December 18, 2020 through January 19, 2024**




Patients 90 and Older: 0

Total Patients	Minimum Age	Maximum Age	Mean Age	Standard Deviation
<b>90</b>	<b>0</b>	<b>16</b>	<b>8</b>	<b>4</b>


**Sex**



**Ethnicity**



**Race**



**Appendix A. List of RxNorm Medication Terms and Healthcare Common Procedure Coding System (HCPCS) Procedure Codes Used to Define Exposures in this Request**

Code	Code Type	Description	Filter
<b>Aducanumab-avwa</b>			
2557217	RxNorm	Aducanumab	
J0172	HCPCS	Injection, aducanumab-avwa, 2 mg	
<b>Amivantamab-vmjw</b>			
2549199	RxNorm	Amivantamab	
C9083	HCPCS	Injection, amivantamab-vmjw, 10 mg	
J9061	HCPCS	Injection, amivantamab-vmjw, 2 mg	
<b>Anifrolumab-fnia</b>			
2565265	RxNorm	Anifrolumab	
C9086	HCPCS	Injection, anifrolumab-fnia, 1 mg	
J0491	HCPCS	Injection, anifrolumab-fnia, 1 mg	
<b>Asciminib</b>			
2584304	RxNorm	Asciminib	
<b>Asparaginase erwinia chrysanthemi (recombinant)-rywn</b>			
1156	RxNorm	Asparaginase	Brand: Rylaze
J9021	HCPCS	Injection, asparaginase, recombinant, (Rylaze), 0.1 mg	
<b>Atogepant</b>			
2571813	RxNorm	Atogepant	
<b>Avacopan</b>			
2572100	RxNorm	Avacopan	
<b>Avalglucosidase alfa-ngpt</b>			
2565814	RxNorm	Avalglucosidase alfa	
C9085	HCPCS	Injection, avalglucosidase alfa-ngpt, 4 mg	
J0219	HCPCS	Injection, avalglucosidase alfa-ngpt, 4 mg	
<b>Belumosudil</b>			
2564025	RxNorm	Belumosudil	
<b>Belzutifan</b>			
2567226	RxNorm	Belzutifan	
<b>Cabotegravir (individually)</b>			
2475077	RxNorm	Cabotegravir	Route: Oral, Injectable; Brand: Apretude, Vocabria
J0739	HCPCS	Injection, cabotegravir, 1 mg	
<b>Cabotegravir and rilpivirine (co-packaged)</b>			
2475077	RxNorm	Cabotegravir	Route: Injectable
1102270	RxNorm	Rilpivirine	Route: Injectable
C9077	HCPCS	Injection, cabotegravir and rilpivirine, 2 mg/3 mg	
J0741	HCPCS	Injection, cabotegravir and rilpivirine, 2 mg/3 mg	
<b>Casimersen</b>			
2480096	RxNorm	Casimersen	
C9075	HCPCS	Injection, casimersen, 10 mg	
J1426	HCPCS	Injection, casimersen, 10 mg	

**Appendix A. List of RxNorm Medication Terms and Healthcare Common Procedure Coding System (HCPCS) Procedure Codes Used to Define Exposures in this Request**

Code	Code Type	Description	Filter
<b>Dasiglucagon</b>			
2535233	RxNorm	Dasiglucagon	
<b>Difelikefalin</b>			
2569089	RxNorm	Difelikefalin	
<b>Dostarlimab-gxly</b>			
2539967	RxNorm	Dostarlimab	
C9082	HCPCS	Injection, dostarlimab-gxly, 100 mg	
J9272	HCPCS	Injection, dostarlimab-gxly, 10 mg	
<b>Drospirenone and estetrol</b>			
11636	RxNorm	Drospirenone	
2539031	RxNorm	Estetrol	
<b>Efgartigimod alfa-fcab</b>			
2587717	RxNorm	Efgartigimod alfa	Brand: Vyvgart
<b>Evinacumab-dgnb</b>			
2478335	RxNorm	Evinacumab	
C9079	HCPCS	Injection, evinacumab-dgnb, 5 mg	
J1305	HCPCS	Injection, evinacumab-dgnb, 5 mg	
<b>Fexinidazole</b>			
2564146	RxNorm	Fexinidazole	
<b>Finerenone</b>			
2562811	RxNorm	Finerenone	
<b>Fosdenopterin</b>			
2531288	RxNorm	Fosdenopterin	
<b>Ibrexafungerp</b>			
2560213	RxNorm	Ibrexafungerp	
<b>Inclisiran</b>			
2588243	RxNorm	Inclisiran	
OMOP5051438	RxNorm	Inclisiran	
<b>Infigratinib</b>			
2550729	RxNorm	Infigratinib	
<b>Loncastuximab tesirine-lpyl</b>			
2540964	RxNorm	Loncastuximab tesirine	
C9084	HCPCS	Injection, loncastuximab tesirine-lpyl, 0.1 mg	
<b>Lonapegsomatropin-tcgd</b>			
2569562	RxNorm	Lonapegsomatropin	
<b>Maralixibat</b>			
2571074	RxNorm	Maralixibat	
<b>Maribavir</b>			
2586068	RxNorm	Maribavir	
<b>Melphalan flufenamide</b>			
2531369	RxNorm	Melphalan flufenamide	
C9080	HCPCS	Injection, melphalan flufenamide HCl, 1 mg	

**Appendix A. List of RxNorm Medication Terms and Healthcare Common Procedure Coding System (HCPCS) Procedure Codes Used to Define Exposures in this Request**

Code	Code Type	Description	Filter
J9247	HCPCS	Injection, melphalan flufenamide, 1 mg	
<b>Mobocertinib</b>			
2570736	RxNorm	Mobocertinib	
<b>Odevixibat</b>			
2563966	RxNorm	Odevixibat	
<b>Olanzapine and samidorphan</b>			
61381	RxNorm	Olanzapine	Brand: Lybalvi
2559612	RxNorm	Samidorphan	Brand: Lybalvi
<b>Pafolacianine</b>			
2586857	RxNorm	Pafolacianine	
<b>Pegcetacoplan</b>			
2557372	RxNorm	Pegcetacoplan	Brand: Empaveli
<b>Piflufolastat F-18</b>			
2556617	RxNorm	Piflufolastat	
A9595	HCPCS	Piflufolastat F-18, diagnostic, 1 mCi	
<b>Ponesimod</b>			
2532300	RxNorm	Ponesimod	
<b>Ropeginterferon alfa-2b-njft</b>			
2587059	RxNorm	Ropeginterferon alfa-2b	
<b>Serdexmethylphenidate and dexamethylphenidate</b>			
2562176	RxNorm	Serdexmethylphenidate	Brand: Azstarys
352372	RxNorm	Dexamethylphenidate	Brand: Azstarys
<b>Sotorasib</b>			
2550714	RxNorm	Sotorasib	
<b>Tepotinib</b>			
2477103	RxNorm	Tepotinib	
<b>Tezepelumab-ekko</b>			
2587789	RxNorm	Tezepelumab	
J2356	HCPCS	Injection, tezepelumab-ekko, 1 mg	
<b>Tisotumab vedotin-tftv</b>			
2571095	RxNorm	Tisotumab	
OMOP5179229	RxNorm	Tisotumab vedotin	
<b>Tivozanib</b>			
2534233	RxNorm	Tivozanib	

**Appendix A. List of RxNorm Medication Terms and Healthcare Common Procedure Coding System (HCPCS) Procedure Codes Used to Define Exposures in this Request**

<b>Code</b>	<b>Code Type</b>	<b>Description</b>	<b>Filter</b>
<b>Tralokinumab-ldrm</b>			
2589225	RxNorm	Tralokinumab	
<b>Trilaciclib</b>			
2479690	RxNorm	Trilaciclib	
<b>Umbralisib</b>			
2478439	RxNorm	Umbralisib	
<b>Vericiguat</b>			
2475830	RxNorm	Vericiguat	
<b>Viloxazine</b>			
11196	RxNorm	Viloxazine	
<b>Voclosporin</b>			
2475166	RxNorm	Voclosporin	
<b>Vosoritide</b>			
2586354	RxNorm	Vosoritide	

**Appendix B. Specifications Defining Query Builder Modules in this Request**

<b>Network:</b>	
USA Minimal Shift network	
<b>Cohort 1: Aducanumab-avwa</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Aducanumab-avwa	December 18, 2020 - most recently available data
<b>Cohort 2: Amivantamab-vmjw</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Amivantamab-vmjw	December 18, 2020 - most recently available data
<b>Cohort 3: Anifrolumab-fnia</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Anifrolumab-fnia	December 18, 2020 - most recently available data
<b>Cohort 4: Asciminib</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Asciminib	December 18, 2020 - most recently available data
<b>Cohort 5: Asparaginase erwinia chrysanthemi (recombinant)-rywn NO FILTER</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Asparaginase erwinia chrysanthemi (recombinant)-rywn	December 18, 2020 - most recently available data

**Appendix B. Specifications Defining Query Builder Modules in this Request**

<b>Cohort 6: Asparaginase erwinia chrysanthemi (recombinant)-rywn BRAND FILTER</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Asparaginase erwinia chrysanthemi (recombinant)-rywn	December 18, 2020 - most recently available data
[FILTER]: Brand name = Rylaze	
<b>Cohort 7: Atogepant</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Atogepant	December 18, 2020 - most recently available data
<b>Cohort 8: Avacopan</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Avacopan	December 18, 2020 - most recently available data
<b>Cohort 9: Avalglucosidase alfa-ngpt</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Avalglucosidase alfa-ngpt	December 18, 2020 - most recently available data
<b>Cohort 10: Belumosudil</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Belumosudil	December 18, 2020 - most recently available data
<b>Cohort 11: Belzutifan</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Belzutifan	December 18, 2020 - most recently available data

**Appendix B. Specifications Defining Query Builder Modules in this Request**

<b>Cohort 12: Cabotegravir OVERALL</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Cabotegravir	December 18, 2020 - most recently available data
<b>Subgroup 1B:</b>	
<i>Cannot Have:</i>	
Rilpivirine	On the same day as subgroup 1A (cabotegravir)
<b>Cohort 13: Cabotegravir ORAL</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Cabotegravir	December 18, 2020 - most recently available data
<i>[FILTER]: Route = Oral</i>	
<b>Cohort 14: Cabotegravir INJECTABLE</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Cabotegravir	December 18, 2020 - most recently available data
<i>[FILTER]: Route = Injectable</i>	
<b>Subgroup 1B:</b>	
<i>Cannot Have:</i>	
Rilpivirine	On the same day as subgroup 1A (cabotegravir)
<b>Cohort 15: Cabotegravir BRAND</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Cabotegravir	December 18, 2020 - most recently available data
<i>[FILTER]: Brand = Apretude or Vocabria</i>	

**Appendix B. Specifications Defining Query Builder Modules in this Request**

<b>Cohort 16: Cabotegravir and Rilpivirine INJECTABLE</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Cabotegravir RxNorm	December 18, 2020 - most recently available data
[FILTER]: Route = Injectable	
<b>Subgroup 1B:</b>	
<i>Must Have:</i>	
Rilpivirine RxNorm	On the same day as subgroup 1A (cabotegravir)
[FILTER]: Route = Injectable	
<b>OR</b>	
<b>Group 2:</b>	<b>Time Restrictions</b>
<b>Subgroup 2A</b>	
<i>Must Have:</i>	
Cabotegravir and Rilpivirine HCPCS	December 18, 2020 - most recently available data
<b>Cohort 17: Casimersen</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Casimersen	December 18, 2020 - most recently available data
<b>Cohort 18: Dasiglucagon</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Dasiglucagon	December 18, 2020 - most recently available data
<b>Cohort 19: Difelikefalin</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Difelikefalin	December 18, 2020 - most recently available data

**Appendix B. Specifications Defining Query Builder Modules in this Request**

<b>Cohort 20: Dostarlimab-gxly</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Dostarlimab-gxly	December 18, 2020 - most recently available data
<b>Cohort 21: Drospirenone and estetrol</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Drospirenone	December 18, 2020 - most recently available data
<b>Subgroup 1B:</b>	
<i>Must Have:</i>	
Estetrol	On the same day as subgroup 1A (drospirenone)
<b>Cohort 22: Efgartigimod alfa-fcab OVERALL</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Efgartigimod alfa-fcab	December 18, 2020 - most recently available data
<b>Cohort 23: Efgartigimod alfa-fcab BRAND</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Efgartigimod alfa-fcab	December 18, 2020 - most recently available data
[FILTER]: Brand name = Vyvgart	
<b>Cohort 24: Evinacumab-dgnb</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Evinacumab-dgnb	December 18, 2020 - most recently available data
<b>Cohort 25: Fexinidazole</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	

**Appendix B. Specifications Defining Query Builder Modules in this Request**

Fexinidazole	December 18, 2020 - most recently available data
<b>Cohort 26: Finerenone</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Finerenone	December 18, 2020 - most recently available data
<b>Cohort 27: Fosdenopterin</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Fosdenopterin	December 18, 2020 - most recently available data
<b>Cohort 28: Ibrexafungerp</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Ibrexafungerp	December 18, 2020 - most recently available data
<b>Cohort 29: Inclisiran</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Inclisiran	December 18, 2020 - most recently available data
<b>Cohort 30: Infigratinib</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Infigratinib	December 18, 2020 - most recently available data
<b>Cohort 31: Loncastuximab tesirine-lpyl</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Loncastuximab tesirine-lpyl	December 18, 2020 - most recently available data

**Appendix B. Specifications Defining Query Builder Modules in this Request**

<b>Cohort 32: Lonapegsomatropin-tcgd</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Lonapegsomatropin-tcgd	December 18, 2020 - most recently available data
<b>Cohort 33: Maralixibat</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Maralixibat	December 18, 2020 - most recently available data
<b>Cohort 34: Maribavir</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Maribavir	December 18, 2020 - most recently available data
<b>Cohort 35: Melphalan flufenamide</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Melphalan flufenamide	December 18, 2020 - most recently available data
<b>Cohort 36: Mobocertinib</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Mobocertinib	December 18, 2020 - most recently available data
<b>Cohort 37: Odevixibat</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Odevixibat	December 18, 2020 - most recently available data

**Appendix B. Specifications Defining Query Builder Modules in this Request**

<b>Cohort 38: Olanzapine and samidorphan OVERALL</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Olanzapine	December 18, 2020 - most recently available data
<b>Subgroup 1B:</b>	
<i>Must Have:</i>	
Samidorphan	On the same day as subgroup 1A (olanzapine)
<b>Cohort 39: Olanzapine and samidorphan BRAND</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Olanzapine	December 18, 2020 - most recently available data
[FILTER]: Brand = Lybalvi	
<b>Subgroup 1B:</b>	
<i>Must Have:</i>	
Samidorphan	On the same day as subgroup 1A (olanzapine)
[FILTER]: Brand = Lybalvi	
<b>Cohort 40: Pafolacianine</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Pafolacianine	December 18, 2020 - most recently available data
<b>Cohort 41: Pegcetacoplan OVERALL</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Pegcetacoplan	December 18, 2020 - most recently available data
<b>Cohort 42: Pegcetacoplan BRAND</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Pegcetacoplan	December 18, 2020 - most recently available data
[FILTER]: Brand = Empaveli	

**Appendix B. Specifications Defining Query Builder Modules in this Request**

<b>Cohort 43: Piflufolastat F-18</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Piflufolastat F-18	December 18, 2020 - most recently available data
<b>Cohort 44: Ponesimod</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Ponesimod	December 18, 2020 - most recently available data
<b>Cohort 45: Ropeginterferon alfa-2b-njft</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Ropeginterferon alfa-2b-njft	December 18, 2020 - most recently available data
<b>Cohort 46: Serdexmethylphenidate and dexmethylphenidate OVERALL</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Serdexmethylphenidate	December 18, 2020 - most recently available data
<b>Subgroup 1B:</b>	
<i>Must Have:</i>	
Dexmethylphenidate	On the same day as subgroup 1A (serdexmethylphenidate)
<b>Cohort 47: Serdexmethylphenidate and dexmethylphenidate BRAND</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Serdexmethylphenidate	December 18, 2020 - most recently available data
[FILTER]: Brand = Azstarys	
<b>Subgroup 1B:</b>	
<i>Must Have:</i>	
Dexmethylphenidate	On the same day as subgroup 1A (serdexmethylphenidate)
[FILTER]: Brand = Azstarys	

**Appendix B. Specifications Defining Query Builder Modules in this Request**

<b>Cohort 48: Sotorasib</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Sotorasib	December 18, 2020 - most recently available data
<b>Cohort 49: Tepotinib</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Tepotinib	December 18, 2020 - most recently available data
<b>Cohort 50: Tezepelumab-ekko</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Tezepelumab-ekko	December 18, 2020 - most recently available data
<b>Cohort 51: Tisotumab vedotin-tftv</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Tisotumab vedotin-tftv	December 18, 2020 - most recently available data
<b>Cohort 52: Tivozanib</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Tivozanib	December 18, 2020 - most recently available data
<b>Cohort 53: Tralokinumab-ldrm</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Tralokinumab-ldrm	December 18, 2020 - most recently available data

**Appendix B. Specifications Defining Query Builder Modules in this Request**

<b>Cohort 54: Trilaciclib</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Trilaciclib	December 18, 2020 - most recently available data
<b>Cohort 55: Umbralisib</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Umbralisib	December 18, 2020 - most recently available data
<b>Cohort 56: Vericiguat</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Vericiguat	December 18, 2020 - most recently available data
<b>Cohort 57: Viloxazine</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Viloxazine	December 18, 2020 - most recently available data
<b>Cohort 58: Voclosporin</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Voclosporin	December 18, 2020 - most recently available data
<b>Cohort 59: Vosoritide</b>	
<b>Group 1:</b>	<b>Time Restrictions</b>
<b>Subgroup 1A</b>	
<i>Must Have:</i>	
Vosoritide	December 18, 2020 - most recently available data